Evolus Inc (EOLS)

$4.93 -0.15 (-2.95%)
Market Cap 305.13M
Revenue (ttm) 297.18M
Net Income (ttm) -51.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -17.38%
Debt to Equity Ratio -6.32
Volume 819,000
Avg Vol 1,107,818
Day's Range N/A - N/A
Shares Out 65.06M
Stochastic %K 89%
Beta 1.00
Analysts Strong Sell
Price Target $15.60

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
Mandi63
Mandi63 Apr. 16 at 4:50 PM
$EOLS $15.50 price target
0 · Reply
buymoremakemore
buymoremakemore Apr. 14 at 11:18 PM
$EOLS Bought 5k shares here. H2 going to be rewarding!
0 · Reply
Mandi63
Mandi63 Apr. 7 at 6:33 AM
$EOLS 90 MILLION EVERY 3 MONTHS . Most companies dream of this success…Price target $15.50
0 · Reply
Arcides
Arcides Apr. 7 at 3:54 AM
$EOLS shorts dream...what a piece of shit this stock has being.
0 · Reply
Mandi63
Mandi63 Apr. 2 at 11:40 AM
$EOLS price target $15.50
0 · Reply
lknite
lknite Mar. 30 at 8:23 PM
$EOLS ouch
1 · Reply
CaliberPalaceTrades
CaliberPalaceTrades Mar. 26 at 3:55 PM
$EOLS
0 · Reply
Bohrenn
Bohrenn Mar. 26 at 11:55 AM
$WVE , $EOLS, $BEAM - mit dem Sharedeals.de No Brainer Club ist eines sicher: manchmal ein Schritt vor (denn die Flut hebt alle Boote), aber häufig 3 Schritte zurück. In Summe verliert man mit der Aktienauswahl vor allem verlässlich Geld.
0 · Reply
BeefStewart
BeefStewart Mar. 25 at 11:00 PM
$EOLS 👀 anyone buying at these levels?
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 15 at 4:58 AM
my approach with $EOLS is simple, wait for H% to get low like this
0 · Reply
Latest News on EOLS
Evolus to Report First Quarter Financial Results on May 4, 2026

Apr 14, 2026, 8:30 AM EDT - 7 days ago

Evolus to Report First Quarter Financial Results on May 4, 2026

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Mar 31, 2026, 8:00 AM EDT - 21 days ago

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2026, 4:05 PM EDT - 4 weeks ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Mar 3, 2026, 4:05 PM EST - 7 weeks ago

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Feb 25, 2026, 8:00 AM EST - 7 weeks ago

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Feb 17, 2026, 8:00 AM EST - 2 months ago

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Jan 9, 2026, 8:30 AM EST - 3 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Evolus Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 5 months ago

Evolus Reports Third Quarter 2025 Financial Results

Evolus to Participate in 2025 Stifel Healthcare Conference

Oct 28, 2025, 8:00 AM EDT - 6 months ago

Evolus to Participate in 2025 Stifel Healthcare Conference

Evolus to Report Third Quarter Financial Results on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Evolus to Report Third Quarter Financial Results on November 5, 2025

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Sep 22, 2025, 9:03 AM EDT - 7 months ago

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2025, 5:30 PM EDT - 7 months ago

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Aug 25, 2025, 8:00 AM EDT - 8 months ago

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Aug 20, 2025, 8:00 AM EDT - 8 months ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 4:05 PM EDT - 9 months ago

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Jul 31, 2025, 8:05 AM EDT - 9 months ago

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 22, 2025, 8:05 AM EDT - 9 months ago

Evolus to Report Second Quarter Financial Results on August 5, 2025

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jul 9, 2025, 8:00 AM EDT - 10 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 11 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 11 months ago

Evolus Announces Departure of its Chief Financial Officer

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22, 2025, 8:00 AM EDT - 11 months ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Evolus Reports First Quarter 2025 Results

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

May 5, 2025, 4:05 PM EDT - 1 year ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Commercial Launch of Evolysse™

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:17 PM EST - 1 year ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Mar 4, 2025, 4:05 PM EST - 1 year ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 27, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 20, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 1 year ago

US FDA approves Evolus' anti-wrinkle gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Feb 13, 2025, 1:30 PM EST - 1 year ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 21, 2025, 8:00 AM EST - 1 year ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 31, 2024, 2:02 PM EDT - 1 year ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:09 PM EDT - 1 year ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus to Report Second Quarter Financial Results on July 31, 2024

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Mandi63
Mandi63 Apr. 16 at 4:50 PM
$EOLS $15.50 price target
0 · Reply
buymoremakemore
buymoremakemore Apr. 14 at 11:18 PM
$EOLS Bought 5k shares here. H2 going to be rewarding!
0 · Reply
Mandi63
Mandi63 Apr. 7 at 6:33 AM
$EOLS 90 MILLION EVERY 3 MONTHS . Most companies dream of this success…Price target $15.50
0 · Reply
Arcides
Arcides Apr. 7 at 3:54 AM
$EOLS shorts dream...what a piece of shit this stock has being.
0 · Reply
Mandi63
Mandi63 Apr. 2 at 11:40 AM
$EOLS price target $15.50
0 · Reply
lknite
lknite Mar. 30 at 8:23 PM
$EOLS ouch
1 · Reply
CaliberPalaceTrades
CaliberPalaceTrades Mar. 26 at 3:55 PM
$EOLS
0 · Reply
Bohrenn
Bohrenn Mar. 26 at 11:55 AM
$WVE , $EOLS, $BEAM - mit dem Sharedeals.de No Brainer Club ist eines sicher: manchmal ein Schritt vor (denn die Flut hebt alle Boote), aber häufig 3 Schritte zurück. In Summe verliert man mit der Aktienauswahl vor allem verlässlich Geld.
0 · Reply
BeefStewart
BeefStewart Mar. 25 at 11:00 PM
$EOLS 👀 anyone buying at these levels?
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 15 at 4:58 AM
my approach with $EOLS is simple, wait for H% to get low like this
0 · Reply
focafoca99
focafoca99 Mar. 14 at 10:46 PM
$EOLS has announced a leadership change
0 · Reply
lknite
lknite Mar. 13 at 5:01 PM
$EOLS great long term buy, probably not even that long term to double your profit
0 · Reply
SnackBandit34
SnackBandit34 Mar. 6 at 4:47 PM
$EOLS Back to 5 bucks.
0 · Reply
CEM97
CEM97 Mar. 5 at 4:16 PM
$EOLS this is $FIGS and $FSLY 2.0
0 · Reply
CEM97
CEM97 Mar. 5 at 3:48 PM
$EOLS if this revisits the highs today I could see $7 Friday or next week
0 · Reply
M105
M105 Mar. 5 at 2:53 PM
$EOLS and…
1 · Reply
M105
M105 Mar. 5 at 2:52 PM
$EOLS
0 · Reply
RocketThief
RocketThief Mar. 4 at 9:24 PM
$EOLS nice turnaround
0 · Reply
RunnerSignals
RunnerSignals Mar. 4 at 9:22 PM
top gainers in the buzz hit major highs today $ASNS $JZXN $BW $EOLS $CANF surge on contracts, crypto deals, earnings beats and clinical wins https://stocksrunner.com/news/2026-03-04-top-gainers-in-the-buzz-today
0 · Reply
STACKD0E
STACKD0E Mar. 4 at 8:50 PM
$EOLS 🙃✨
0 · Reply
StockJelli
StockJelli Mar. 4 at 8:39 PM
Last 20 min of power hour. Here are the momentum tickers. $BDMD $EOLS $GEMI $DAWN $ZIP
0 · Reply
SnackBandit34
SnackBandit34 Mar. 4 at 8:36 PM
$EOLS Let’s go back to 5🔥🔥
0 · Reply